Starting from June 15, 2026, the U.S. FDA has introduced clearer compliance requirements for medical-grade temperature and humidity sensors entering the U.S. market: when submitting registration materials for related products, ISO 10993 biocompatibility test reports and IEC 61000-4 series EMC electromagnetic compatibility reports must also be provided. This change is not only an increase in testing items, but also means that the compliance threshold for export, private-label branding, distribution, and end-market integration has been raised, and relevant companies need to reassess their existing processes in customs clearance, delivery, and after-sales risk management.

What exactly does this update require?

Available information confirms that the U.S. Food and Drug Administration (FDA) officially implemented the 《Medical Sensor Compliance Guidance Update》 on June 15, 2026. The new requirements apply to all medical-grade temperature and humidity sensors entering the U.S. market, covering product forms such as transmitters and smart probes, and require the simultaneous submission of ISO 10993 biocompatibility test reports and IEC 61000-4 series EMC electromagnetic compatibility reports.

The scope of these requirements is not limited to manufacturers; it also includes OEM private-label businesses, import distributors, and end-system integrators. For products that do not meet the requirements, there is a clearly identified risk of customs rejection or market recall. According to the input information, this regulatory change will directly affect the compliant export paths of more than 200 Chinese exporters of temperature and humidity sensors.

After the compliance requirements move forward, it is not only the manufacturing side that is affected

Export manufacturers face a dual adjustment in documentation and delivery

From an industry perspective, the first to be directly affected are export-oriented temperature and humidity sensor manufacturers. The reason is that the new rules have made the core supporting documents required for entering the U.S. market more specific; companies can no longer respond only with product functionality, routine testing, or customer factory inspection thinking, but must revalidate existing product data around biocompatibility and EMC dual reports. The most directly affected business stages are shipment inspection arrangements, technical document preparation, pre-shipment review, and delivery schedule control.

What such companies currently need to focus on is not only whether their own products fall within the scope of medical-grade temperature and humidity sensors, whether existing test documents can meet the new requirements, and whether the report documents in the export package are already complete and trade-chain ready.

The boundary of responsibility becomes more blurred for OEM private-label and end-system integration stages

For OEM private-label and end-system integrators, the significance of this change lies in the fact that the applicable entities are now clearly identified. Analysis shows that market entry responsibility can no longer be simply attributed to the original manufacturer; both the private-label party and the integrator also need to confirm whether dual reports are complete when selecting models, purchasing, and delivering projects. If front-end procurement focuses only on price and lead time while ignoring documentation completeness, subsequent risks may be exposed during customs clearance or market circulation.

Accordingly, these business roles need to incorporate compliance document verification into procurement, project acceptance, and outbound supply document management, especially ensuring that the specifications, packing list, and supporting materials are consistent with the actual delivered products.

Import distribution and channel circulation pay more attention to customs clearance and recall risks

For import distribution and channel circulation companies, the core change brought by the new rules is not the product definition itself, but the practical elevation of trade and circulation responsibility. Available information has already indicated that non-compliant products may be refused customs clearance or face market recall, so distribution links need to place greater emphasis on document completeness, supply-source compliance, and after-sales traceability readiness.

What such companies need to focus on is not only whether they have obtained the reports, but also whether the reports can form a closed-loop delivery chain with the corresponding products, batches, or project materials. Otherwise, even if front-end transactions are completed, risks may still appear later during import, delivery, or market maintenance.

Testing and certification-related service links may bear more verification demands

From an observational perspective, once dual reports become a clear requirement for entering the U.S. market, service demand around testing, document organization, and compliance verification may rise. What is more worthy of attention here is not the size of the demand, but the increase in enterprises' sensitivity to report adaptability, data completeness, and delivery timing. What relevant service institutions need to face in business is more the matching issue between reports and product use or trade use.

What should companies now focus on in practical terms?

First, verify whether existing product data has any gaps

For companies that have already exported to, or are preparing to enter, the U.S. market, the first thing to do now is not to expand judgment, but to check product data item by item. The key points are: whether existing medical-grade temperature and humidity sensors already have ISO 10993 biocompatibility test reports and IEC 61000-4 series EMC electromagnetic compatibility reports; if some test data already exists, whether it can meet the submission requirements after this update. The input information did not provide a more refined execution path, so this step is more appropriately understood as a compliance self-check rather than a prediction of the outcome.

Include report documents as preconditions for procurement and delivery

From the analysis, once the dual report requirement becomes a clear prerequisite for market entry, buyers, private-label parties, and integrators need to adjust the relevant reports from "supplementary materials" to "pre-positioned documents". This will affect supplier onboarding, procurement cadence, project scheduling, and outbound delivery preparation. Especially in multi-party cooperation models, who is responsible for providing, updating, and filing the relevant reports should be clarified as early as possible in contracts, orders, or technical documents.

Pay attention to whether customs clearance, recall, and after-sales traceability are connected

Because non-compliant products have been explicitly indicated as facing customs rejection and market recall risks, companies need to simultaneously check whether their trade documents, shipping materials, and after-sales traceability mechanisms can align with each other. For exporters and distributors, the issue is not only whether reports exist, but whether the reports can support actual trade circulation and subsequent market management. What is currently more worthy of attention is whether compliance data management can run through pre-shipment, import, and after-sales stages.

Continue to monitor subsequent execution paths and market document changes

The input information has confirmed that the rule has taken effect, but it has not yet laid out more specific execution details. Observationally, companies still need to keep an eye on whether official statements, customer procurement documents, project tender documents, and channel-side material requirements become further refined. For projects already in execution, whether supplementary documents, certification changes, or delivery schedule adjustments are needed should also be tracked cautiously, rather than being concluded in advance.

How should this information be understood?

Overall, this event reflects not a simple increase in testing requirements, but that the compliance path for medical temperature and humidity sensors exporting to the U.S. is becoming more specific and more front-loaded. The impact covers not only manufacturers, but also multiple links such as OEM private-label businesses, import distribution, and end-system integration. For relevant companies, the more appropriate current understanding is: this is an entry-condition change that has already taken effect; in the short term, priority should be given to verifying reports, certificates, and delivery processes, while in the medium term, execution paths and market feedback should continue to be observed, rather than exaggerating the result or ignoring its practical impact.

Source basis and subsequent verification direction

This article is generated based on the title, event time, and summary provided by the user, and the information used includes: the June 15, 2026 time point, the official implementation of FDA's 《Medical Sensor Compliance Guidance Update》, the requirement for medical-grade temperature and humidity sensors to submit ISO 10993 and IEC 61000-4 series reports in sync, the applicable scope covering OEM private-label businesses, import distributors, and end-system integrators, as well as the possibility that non-compliant products may be refused customs clearance or face market recall.

According to the normal verification path for such events, subsequent attention may continue to be paid to official announcements, regulatory releases, trade or customs-related information, industry association updates, standard organization documents, and authoritative media reports. It should be noted that the input content did not provide specific official source links, so specific official links still need continuous verification later; at the same time, policy details, certification execution paths, tender document changes, industry feedback, and actual corporate implementation conditions will remain key points for subsequent observation.